Drug intelligence / Profile preview

daclatasvir + asunaprevir + beclabuvir

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

**Daclatasvir + asunaprevir + beclabuvir** is an oral fixed-dose combination of three small-molecule direct-acting antivirals developed by Bristol Myers Squibb for chronic hepatitis C virus infection. Daclatasvir inhibits the HCV NS5A replication complex, asunaprevir inhibits the HCV NS3/4A serine protease, and beclabuvir is a nonnucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase. The combination was marketed in Japan as **Ximency** for improvement of viremia in patients with genotype 1 chronic hepatitis C or compensated cirrhosis, administered as two tablets twice daily after meals for 12 weeks.

Brand names: Ximency
Other names: 3DAA regimendaclatasvir + asunaprevir + BMS-791325daclatasvir/asunaprevir/beclabuvirDCV 3DAA regimenDCV3DAA regimenDCV-3DAA regimenDCV-TRIODCV/ASV/BMS-791325

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on daclatasvir + asunaprevir + beclabuvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daclatasvir + asunaprevir + beclabuvir.

Explore the full profile